About Us – Team & Advisory

As a member of the Board of Directors, Christian Hälg ensures clear structures, strategic foresight, and sound governance. His experience with leading Swiss corporations strengthens investor confidence and guides the company’s long-term direction.

As CEO, Christian Hälg drives the operational growth of Heimat Manufaktur AG. With an analytical mindset and pragmatic leadership, he advances innovation, secures sustainable growth, and maintains Heimat’s premium market position.

As a member of Heimat’s Board of Directors, Sam Wüst brings profound entrepreneurial know-how and a solid foothold in the Swiss retail and consumer goods sector. His expertise strengthens Heimat Manufaktur AG’s reach within Switzerland’s retail landscape and supports the company’s ambition to scale sustainably and authentically – with market proximity and genuine entrepreneurial drive at its core.

Managing Director Heimat Manufaktur GmbH (Austria)
With Reinhard Leitner serving as Managing Director of its Austrian subsidiary, Heimat Manufaktur AG operates with dedicated executive leadership in one of its strategically most important neighbouring markets. As Country Lead Austria, he holds full responsibility for the business activities of Heimat Manufaktur GmbH – from strategic market development and day-to-day operations to representing the company before authorities, partners and investors.
His remit covers the strategic direction and governance of the Austrian market, the development of sales, distribution and retail structures, regulatory compliance and the financial and operational performance of the subsidiary. Reinhard Leitner leads the Austrian team, oversees brand presence on the ground and ensures close alignment with the Swiss parent company – in content, culture and governance.
With more than two decades of leadership experience in highly regulated, consumer-facing markets, Reinhard Leitner brings a rare profile: entrepreneurial sharpness, deep familiarity with the Austrian market and a robust network across business, government and retail. His leadership style combines strategic clarity with operational execution strength – qualities essential for building a stand-alone, profitable and regulatory-compliant market presence.
His role at Heimat: As Managing Director of Heimat Manufaktur GmbH, Reinhard Leitner is responsible for all business activities in Austria – including strategy, sales, operations, compliance, leadership and stakeholder management. For investors, his role represents one thing: a dedicated, professionally managed market presence in Austria, with a clear governance structure and an experienced Country Lead at the helm.

Country Lead Switzerland – Sales, Distribution & Market Development
With Fabio Martins as Country Lead Switzerland, Heimat Manufaktur AG operates with experienced executive leadership in its home and core market. In this role, he is responsible for the strategic market development, the build-up and steering of sales and distribution structures and the brand presence of Heimat Manufaktur AG across the entire Swiss market – from retail and the pharmacy segment to strategic partnerships.
His remit covers market strategy and penetration, the development and scaling of sales channels, the acquisition and management of key accounts, the national roll-out of new product segments and the operational leadership of the sales team. Fabio Martins ensures that Heimat’s brand promise – authenticity, premium quality and Swiss provenance – is consistently brought to life at every touchpoint along the value chain.
His career spans more than fifteen years of leadership and sales experience in consultative, regulated and consumer-facing industries. He brings deep expertise in building and scaling sales structures, in steering complex, consultative sales processes and in institutional stakeholder management. In previous executive roles, he led the marketing of demanding asset portfolios, established structures, processes and reporting standards and managed complex transactions from first contact to successful closing.
This combination of institutional sales strength, entrepreneurial market proximity and deep understanding of consultative sales processes makes him an ideal fit for the Country Lead role in a market that is built equally on quality, trust and personal relationships. Fabio Martins understands sales not as a standardised process but as a relationship-driven dialogue – a mindset that aligns precisely with the brand philosophy of Heimat Manufaktur AG.
His role at Heimat: As Country Lead Switzerland, Fabio Martins is responsible for all market activities of Heimat Manufaktur AG in Switzerland – including strategy, sales, distribution, key accounts, brand presence and stakeholder management. For investors, his role represents one thing: a professionally led, relationship-driven and sustainably growth-oriented market approach in Heimat Manufaktur AG’s home market.

Daniel Haymann is one of Europe’s leading legal advisors in the cannabis, healthcare and life sciences sector. With his appointment to the Advisory Board of Heimat Manufaktur AG, the company anchors deep regulatory expertise directly at its Swiss headquarters – establishing the foundation for a robust, cross-border compliance architecture across the DACH region and beyond.

Daniel Haymann advises investors, start-ups and vertically integrated companies along the entire value chain – with a particular focus on regulatory matters related to THC, CBD and further cannabinoids and psychoactive substances, GMP and GDP standards, food and cosmetics law, as well as authorisation procedures before Swissmedic, the Swiss Agency for Therapeutic Products.

As Co-Founder and Co-Chair of INCBA Europe (International Cannabis Bar Association), he brings a unique international network and a depth of industry expertise rarely found in Europe. His prior experience in international commodity trading sharpens his understanding of complex markets, trading structures and cross-border supply chains – a strategic advantage in the globally interconnected cannabis and healthcare sector.

His role at Heimat: Daniel Haymann safeguards Heimat Manufaktur AG’s regulatory interface across Switzerland and the EU – from Swissmedic authorisation procedures and GMP-/GDP-compliant production and distribution structures to the legal governance of the medical cannabis segment and international partnerships. For investors, his presence on the Advisory Board signals one thing above all: dependable regulatory reliability in one of the world’s most demanding therapeutic product markets.

Dr. Fabienne Diekmann Advisory Board – Legal & Regulatory Germany

With the appointment of Dr. Fabienne Diekmann to its Advisory Board, Heimat Manufaktur AG anchors one of Germany’s most distinguished legal experts for regulated consumer and healthcare products at the heart of its German market strategy. Her appointment marks a deliberate move: Heimat’s entry into the German market is not opportunistic but built on a robust regulatory, approval-related and distribution architecture.

As Co-Owner of the Hamburg-based commercial law firm DIEKMANN Rechtsanwälte, Dr. Diekmann has advised companies along the entire value chain since 2007 in the fields of cannabis, pharmaceuticals, medical devices, food, food supplements, cosmetics, tobacco and biocides – from product development, classification questions, formulations and Novel Food authorisations through to labelling, advertising and contract drafting. For Heimat, this scope of expertise reflects a rare alignment with the company’s own product portfolio – from premium cannabis and medical THC to traditional tobacco, snus and functional lifestyle products.

Her expertise covers in particular authorisation, registration and notification procedures, the review of claims and health claims, as well as the development of private-label strategies, including for pharmacies and pharmacy cooperations. Through her co-founding of PharmSec International GmbH, she additionally supports companies in obtaining wholesale, narcotics and MedCanG trading licences (§ 52a AMG, § 3 BtMG, § 4 MedCanG) – a strategically decisive lever for Heimat’s medical cannabis segment in Germany.

Dr. Diekmann has built a robust network at EU, federal and state authority level over many years, as well as with leading industry associations. She is a member of, among others, Pharma Deutschland, INTEGRITAS – Association for Fair Health Product Advertising, the German-French Lawyers’ Association and Avolink.

Her role at Heimat: Dr. Diekmann leads the legal and regulatory governance of Heimat’s German expansion – from compliance in pharmaceutical, cannabis and food law to market entry and distribution structures and authority interface management. For investors, her appointment delivers above all one thing: a measurable reduction of regulatory risk and a clearly structured path into Europe’s most significant cannabis market.

With Dr. Sebastian Marincolo, Heimat Manufaktur AG gains one of Europe’s most distinguished strategists at the intersection of cannabis, brand leadership and public communications. His appointment to the Advisory Board sends a deliberate signal: Heimat’s brand architecture is not built on generic cannabis codes but on a differentiated, evidence-based and culturally resonant foundation.

As Director of Communications & Marketing at Canopy Growth, one of the world’s largest publicly listed cannabis companies, Dr. Marincolo led brand development, internal communications and market expansion across Europe. Today, he advises leading brands as a strategic communications expert – helping them build clear identities and position themselves sustainably in the highly regulated cannabis market.

Beyond his brand expertise, Dr. Marincolo is an internationally recognised authority on consciousness research and the psychoactive effects of cannabis. He holds a PhD in Philosophy magna cum laude from the University of Tübingen and conducted research at the University of North Carolina. As a bestselling author, publicist and sought-after speaker, he has shaped the scientific and cultural discourse on cannabis and altered states of consciousness for more than two decades – at conferences, in academic publications and as a respected voice within the international cannabis community.

His role at Heimat: Dr. Marincolo supports Heimat Manufaktur AG’s brand positioning, strategic communications and educational outreach across the DACH region and at European level – with particular focus on the medical cannabis segment, the HEIMATKULT premium line and the company’s scientifically grounded external perception. For investors, his contribution stands for one thing: brand leadership that combines regulatory sensitivity, cultural depth and commercial scalability in equal measure.

With Gianclaudio Floria, Heimat Manufaktur AG gains one of the most distinguished international experts in pharma market access, pricing strategy and commercial forecasting for the further development of its medical cannabis segment. His appointment to the Advisory Board sharpens the pharmaceutical standard with which Heimat leads its medical division across the DACH region – evidence-based, pharmacy-grade and on par with established therapeutic product providers.With more than 20 years of international experience across Italy, the United Kingdom, Switzerland and the United States, Gianclaudio Floria has held senior leadership positions at Bristol Myers Squibb (Global Head of Multiple Myeloma & Lymphoma Pricing), Alexion (Senior Director, Head of Complement Franchise Market Access International), Fresenius Kabi Biosimilars (Senior Director, Global Head of Pricing & Market Access), Amgen (Regional Access & Pricing Lead Europe and Global Launch Sequence assignment in California) and Gilead Sciences (Forecasting Associate Director, EU iHQ London). His proven expertise spans haemato-oncology, immuno-oncology, nephrology, infectious diseases, rare diseases and biosimilars – covering precisely those therapeutic areas in which standardised cannabinoid applications carry the greatest clinical evidence and reimbursement relevance, including chronic, inflammatory and neuropathic pain syndromes, supportive oncology and selected neurological applications. His professional depth covers the entire value chain of pharmaceutical market entry: price and market access strategy, payer research and launch sequencing, innovative contracting models (Managed Entry Agreements), International Reference Pricing (IRP) and tender strategies, and AI-driven forecasting, patient tracking and scenario-based market modelling. As Founder and Managing Director of Bright Light Consulting GmbH (Zug), he advises pharma and medtech clients across analytics, forecasting and market access – backed by Six Sigma Green Belt certification and recognised methodological rigour (three-time Microsoft MVP for Excel, author of multiple business and finance books, regular speaker at the European Pricing Platform and other industry conferences).His role at Heimat: Gianclaudio Floria supports the strategic governance of Heimat Manufaktur AG’s medical cannabis segment with particular focus on the pharmaceutical positioning of the portfolio, the DACH-wide pricing and launch sequencing architecture (Switzerland, Austria, Germany), the further development of pharmacy-grade proprietary products and white-label solutions for the Swiss pharmacy wholesalers (Galexis, Pharmafocus, Avosana, Zur Rose), the build-up of evidence-based payer dossiers and reimbursement pathways, as well as the commercial preparation for the regulated cannabis market following the entry into force of the Swiss Cannabis Products Act. Beyond the pharma agenda, he also accompanies Heimat’s international expansion – contributing his cross-border experience in market entry, launch sequencing and commercial scaling across Europe and the United States.Education & credentials: MBA, MIB School of Management; Degree in Political Economy, University of Trieste; Six Sigma Green Belt; three-time Microsoft MVP for Excel. Languages: Italian (mother tongue), English (fluent), German and Spanish (working knowledge).

In Dr. Mathias Rodenstein, Heimat Manufaktur AG gains a rare combination of scientific depth, Big Four regulatory experience and entrepreneurial market proximity. His contribution to the Advisory Board anchors a consistently risk- and governance-oriented perspective at the strategic core of the company.

With more than 13 years at PwC as Senior Project Manager in Risk Management for financial services, Dr. Rodenstein brings top-tier expertise in credit risk, operational risk, regulatory compliance (BCBS, FINMA, EMIR/FinfraG), data-driven risk modelling and BI-based reporting. Backed by his analytical foundation in materials science (ETH Zurich), he ensures that Heimat’s cannabis and financial operations meet the highest standards in governance, risk mitigation and scalable implementation.

His complementary experience as a self-employed trader and market analyst, alongside earlier roles in investment promotion (British Embassy) and strategy consulting (Roland Berger), makes him a versatile strategist – equally accomplished in quantitative modelling, market positioning and investor relations.

His role at Heimat: Dr. Rodenstein leads the strengthening of Heimat Manufaktur AG’s governance, risk and compliance architecture – from the design of internal control systems and regulatory frameworks to the data-driven steering of the company’s growth. For investors, his contribution stands for institutional robustness, transparent reporting structures and scalable risk governance at Big Four level.

Heinz Wälti is regarded as a pioneer of modern Swiss retail and shaped one of Switzerland’s most recognised retail brands for more than two decades. With his appointment to the Advisory Board of Heimat Manufaktur AG, the company anchors hands-on expansion experience and institutional knowledge of scalable distribution models at the heart of its growth strategy.

For 26 years, Heinz Wälti served as CEO of LANDI Switzerland, transforming a traditional cooperative into one of Switzerland’s most popular and trusted retail concepts – with a 52-fold increase in sales. He was instrumental in developing the standardised LANDI store model – covering logistics, marketing, staff training, roll-out and national expansion – laying the foundation for LANDI’s enduring success today.

Beyond his strategic and operational strength, Heinz Wälti is recognised for his authentic leadership style, his deep connection to people and regions and his ability to inspire and retain teams at every level.

His role at Heimat: Heinz Wälti supports Heimat Manufaktur AG in the development of scalable retail and distribution structures – from store and location strategy and the roll-out of the HEIMAT HUB (24/7 automated POS solution) to distribution partnerships with pharmacies, retailers and partner networks across Switzerland and the DACH region. For investors, his contribution stands for one thing: a proven expansion model, carried by an architect of modern Swiss retail.

Prof. Dr. med. Felix Niggli combines leading medical expertise with a profound sense of social responsibility. Through his contribution to the Advisory Board of Heimat Manufaktur AG, the company anchors scientific integrity and ethical depth directly within the governance of its medical cannabis segment – a deliberate commitment to the evidence-based advancement of therapeutic applications.

As a renowned paediatric oncologist and board member of the Kinderhilfe Sternschnuppe Foundation, Prof. Niggli stands for decades of clinical experience, academic reputation and a patient-centred research approach. His expertise underpins the scientific credibility and clinical relevance of Heimat Manufaktur AG’s medical cannabis segment.

Within the Advisory Board, he guides the strategic direction of the medical division with scientific rigour, the highest ethical standards and a clear focus on therapeutic value – particularly in pain therapy, supportive oncology as well as paediatric and neurological applications.

His role at Heimat: Prof. Niggli guides the scientific and ethical governance of Heimat Manufaktur AG’s medical cannabis segment – from clinical partnerships and the interface with pharmacies, hospitals and research institutions to positioning within medical professional circles. For investors, his contribution stands for medical credibility, scientific substance and a reliable compass for responsible growth in the therapeutic product sector.